Advertisement
Canada markets open in 2 hours 27 minutes
  • S&P/TSX

    21,942.16
    +148.26 (+0.68%)
     
  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     
  • DOW

    39,164.06
    +36.26 (+0.09%)
     
  • CAD/USD

    0.7306
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    82.37
    +0.63 (+0.77%)
     
  • Bitcoin CAD

    84,131.39
    +541.12 (+0.65%)
     
  • CMC Crypto 200

    1,282.18
    -1.65 (-0.13%)
     
  • GOLD FUTURES

    2,346.10
    +9.50 (+0.41%)
     
  • RUSSELL 2000

    2,038.34
    +20.22 (+1.00%)
     
  • 10-Yr Bond

    4.2880
    -0.0280 (-0.65%)
     
  • NASDAQ futures

    20,128.75
    +89.25 (+0.45%)
     
  • VOLATILITY

    12.33
    +0.09 (+0.74%)
     
  • FTSE

    8,225.63
    +45.95 (+0.56%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     
  • CAD/EUR

    0.6819
    +0.0002 (+0.03%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.